KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Cash from Operations (2016 - 2025)

Historic Cash from Operations for Travere Therapeutics (TVTX) over the last 16 years, with Q3 2025 value amounting to $14.3 million.

  • Travere Therapeutics' Cash from Operations rose 13368.15% to $14.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$58.6 million, marking a year-over-year increase of 7797.53%. This contributed to the annual value of -$237.5 million for FY2024, which is 2701.09% up from last year.
  • Per Travere Therapeutics' latest filing, its Cash from Operations stood at $14.3 million for Q3 2025, which was up 13368.15% from $5.0 million recorded in Q2 2025.
  • In the past 5 years, Travere Therapeutics' Cash from Operations registered a high of $32.1 million during Q3 2021, and its lowest value of -$119.0 million during Q1 2024.
  • Over the past 5 years, Travere Therapeutics' median Cash from Operations value was -$42.5 million (recorded in 2024), while the average stood at -$48.6 million.
  • As far as peak fluctuations go, Travere Therapeutics' Cash from Operations soared by 37606.53% in 2021, and later tumbled by 66659.48% in 2022.
  • Over the past 5 years, Travere Therapeutics' Cash from Operations (Quarter) stood at -$88.3 million in 2021, then increased by 13.16% to -$76.7 million in 2022, then grew by 16.08% to -$64.4 million in 2023, then skyrocketed by 44.51% to -$35.7 million in 2024, then surged by 140.08% to $14.3 million in 2025.
  • Its last three reported values are $14.3 million in Q3 2025, $5.0 million for Q2 2025, and -$42.2 million during Q1 2025.